Rates of Serious Intracellular Infections in Autoimmune Disease Patients Receiving Initial Glucocorticoid Therapy

Kiyoshi Migita*, Toru Arai, Naoki Ishizuka, Yuka Jiuchi, Yasuharu Sasaki, Yasumori Izumi, Tetsuyuki Kiyokawa, Eiichi Suematsu, Tomoya Miyamura, Hiroshi Tsutani, Yojiro Kawabe, Ryutaro Matsumura, Shunsuke Mori, Shiro Ohshima, Shigeru Yoshizawa, Kenji Kawakami, Yasuo Suenaga, Hideo Nishimura, Toyohiko Sugimoto, Hiroaki Iwase, Hideyuki Sawada, Haruhiro Yamashita, Shigeyuki Kuratsu, Fumitaka Ogushi, Masaharu Kawabata, Toshihiro Matsui, Hiroshi Furukawa, Seiji Bito, Shigeto Tohma

Japanese National Hospital Organization (NHO)-EBM study group for Adverse Effects of Corticosteroid Therapy (J-NHOSAC), Meguro, Tokyo, Japan

Abstract

Background/Aims: The Japanese National Hospital Organization evidence-based medicine (EBM) Study group for Adverse effects of Corticosteroid therapy (J-NHOSAC) is a Japanese hospital-based cohort study investigating the safety of the initial use of glucocorticoids (GCs) in patients with newly diagnosed autoimmune diseases. Using the J-NHOSAC registry, the purpose of this observational study is to analyse the rates, characteristics and associated risk factors of intracellular infections in patients with newly diagnosed autoimmune diseases who were initially treated with GCs.

Methodology/Principal Findings: A total 604 patients with newly diagnosed autoimmune diseases treated with GCs were enrolled in this registry between April 2007 and March 2009. Cox proportional-hazards regression was used to determine independent risk factors for serious intracellular infections with covariates including sex, age, co-morbidity, laboratory data, use of immunosuppressants and dose of GCs. Survival was analysed according to the Kaplan-Meier method and was assessed by the log-rank test. There were 127 serious infections, including 43 intracellular infections, during 1105.8 patient-years of follow-up. The 43 serious intracellular infections resulted in 8 deaths. After adjustment for covariates, diabetes (Odds ratio [OR]: 2.5, 95% confidence interval [95% CI] 1.1–5.9), lymphocytopenia (≤1000/μl, OR: 2.5, 95% CI 1.2–5.2) and use of high-dose (>30 mg/day) GCs (OR: 2.4, 95% CI 1.1–5.3) increased the risk of intracellular infections. Survival curves showed lower intracellular infection-free survival rate in patients with diabetes, lymphocytopenia and high-dose GCs treatments.

Conclusions/Significance: Patients with newly diagnosed autoimmune diseases were at high risk of developing intracellular infection during initial treatment with GCs. Our findings provide background data on the risk of intracellular infections of patients with autoimmune diseases. Clinicians showed remain vigilant for intracellular infections in patients with autoimmune diseases who are treated with GCs.

Introduction

Despite the considerable benefits of glucocorticoids (GCs) in controlling serious inflammation and improving the functional status of a plethora of disorders [1], serious adverse effects dampen the enthusiasm for their use, particularly long-term [2]. Bacterial and fungal infections are the most common serious infections occurring in patients receiving GCs [3], although intracellular infections are also a concern [4]. Moderate- to high-dose GC therapy leads to an increased risk of opportunistic infections, including intracellular infections [5,6]. However, there is little information regarding the rate of intracellular infection in a large series of patients receiving GCs in clinical practice. Most studies of GCs toxicity are retrospective and risk factors for intracellular infections have not been completely elucidated in prospective studies. Because immunosuppression induced by GCs is broad, a wide variety of pathogens can infect hosts treated with GCs [7]. Thus, the clinician must anticipate both usual and unusual infections, including intracellular infections. There is a paucity of well-controlled studies detailing the infectious risks, particularly concerning intracellular infections, and much of the information is in the form of case reports and literature reviews [8,9]. In addition, many of these reports offer little detail regarding the dose or duration of GC administration.

The Japanese National Hospital Organization evidence-based medicine (EBM) Study group for Adverse effects of Corticosteroid
therapy (J-NHOSAC) is a Japanese non-interventional prospective study, based on a nationwide registry of severe adverse events (AEs) in newly diagnosed autoimmune disease patients treated with moderate doses of GCs in a clinical setting [10]. This original strategy can be used to determine the exact incidence of serious infections and their risk factors and using the J-NHOSAC registry we previously reported that infections were the most common AEs occurring in newly diagnosed autoimmune disease patients, who were initially treated with GCs [10]. The aim of this study was to describe cases of intracellular infections, and to identify risk factors for their occurrence.

Materials and Methods

Patients and Study design

Patients were eligible for the study if they were initially treated with GCs for a recently diagnosed (within 4 weeks prior to study entry) autoimmune disease using established criteria. The cohort start date was defined as the time of initiation of the first GC prescription. The autoimmune diseases registered in this study were as follows. Rheumatic diseases: SLE (systemic lupus erythematosus), MCTD (mixed connective tissue disease), polymyositis, dermatomyositis, vasculitis, Behçet disease, systemic scleroderma, AOSD (adult onset Still disease), Sjögren syndrome, rheumatoid arthritis, autoimmune bullous diseases, and anaphylactoid purpura. Neurological diseases: multiple sclerosis, myasthenia gravis, and CIDP (chronic inflammatory demyelinating polyradiculoneuropathy). Gastro-hepatobiliary diseases: ulcerative colitis, autoimmune hepatitis, autoimmune pancreatitis, and PBC (primary biliary cirrhosis). Interstitial lung diseases: idiopathic interstitial pneumonia and collagen vascular disease preceded by interstitial pneumonia. Primary glomerular diseases: rapidly progressive glomerulonephritis, chronic glomerulonephritis, and nephrotic syndrome.

A total of 604 patients with newly diagnosed autoimmune disease were enrolled between April 1, 2006 and March 31, 2008, and regularly followed concerning the occurrence of GC-related adverse effects. The observation period ended on March 31 2009. Before implementation of this study, institutional review board and ethics committee approvals of the protocol and the consent to participate in the study and consent to publish were obtained from each of the participating patients. The study was approved by the ethical committees of the National Hospital Organization (NHO) central internal review board (No. 0512014, 2006). Written informed consent was obtained from each individual.

Data collection

Data from all participating physicians were entered into the J-NHOSAC database at the data centre of the International Medical Center of Japan in Tokyo, Japan via the HOSPnet internet system. Serious infections were defined as those that led to hospitalization or death or required intravenous antibiotic treatment. If a serious infection was identified from the patient’s medical records provided by participating doctors. If not already provided, additional information regarding all serious infections was requested, including causative organism.

Data on study entry

The past comorbid condition of each patient was reviewed by each of the principle physicians. These conditions included renal, neurological, endocrine, cardiovascular and pulmonary diseases as well as cancer and stroke. In addition, the incidences of specific conditions, including pre-existing pulmonary tuberculosis, hepatitis viral infection (HBV, HCV), diabetes, hyperlipidaemia, arrhythmia and performance status (Karnofsky score) were assessed. The physicians also provided information on smoking or drinking habits and history of tuberculosis (TB). At entry, patients underwent chest X-ray and were screened for surface hepatitis B virus antigen (HBs Ag) and anti-HCV antibodies.

Outcome variables

At the start of the study, standardized lists were used to document AEs, which were classified using the System Organ Class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA; version 11.1). All physicians documented episodes of infection requiring medical care and death certificates and the causes of deaths that occurred during the follow-up periods. Serious infections occurring during the observation periods were counted. Serious infections ≥ grade 3, by common terminology of Adverse Events v3.0 [CTCAE], were defined as life-threatening, requiring hospitalization and/or intravenous antibiotic therapy, or leading to significant disability/incapacitily [11]. Infections were coded by anatomic site and by causal organism. Cytomegalovirus (CMV) infection was defined as CMV end-organ disease, in which the signs and symptoms of affected organs (pneumonia, gastrointestinal disease, or hepatitis) plus CMV antigenemia were present. The diagnosis of CMV antigenemia was defined by a positive CMV PP65 antigenemia assay [12]. A diagnosis of Pneumocystis pneumonia (PCP) was made according to the established criteria for PCP [13]. The diagnosis of PCP was considered presumptive if a patient fulfilled the clinical and radiographic conditions in the absence of evidence of other infectious diseases and in the presence of either a positive PCR test for Pneumocystis jiroveci DNA (qualitative PCR analysis by SRL, Tokyo, Japan) or increased serum β-D-glucan levels above the upper limit of normal (ULN) (Fungitec G test MK; Seikagaku, Tokyo, Japan) and responded to standard treatments for PCP with trimethoprim/sulfamethoxazole (TMP/SMX) or pentamidine isethionate. Both the PCR test for P. jiroveci DNA and the serum BDG test are commercially available, validated, and officially approved as clinical laboratory tests by the Ministry of Health, Labour, and Welfare in Japan.

Follow-up data

Patients were followed up every 3 months by the chief physician for each of the NHO hospitals, who collected clinical findings (disease activity, severity, performance status, blood pressure, body weight) and laboratory data (complete blood cell count, biochemistry, and urinalysis). The telephone interview concerning the health assessment and the presence of GCs-related AEs was conducted against few patients who were moved or transferred to another hospital at the end of cohort. However, overall outcome was not available from 14 patients (2.3%) at the end of study. In statistical analysis, we excluded these participants without final outcome data.

Medications

Details of GCs, immunosuppressants, and biologics were recorded at each visit, including the route of administration and dose. We categorized GC exposure according to the mean daily dose throughout the follow-up period for each patient. We calculated “dose equivalents” of prednisolone as follows: 1 mg of prednisolone = 5 mg of cortisone = 4 mg of hydrocortisone = 1 mg of prednisone = 0.8 mg of triamcinolone = 0.8 mg of methylprednisolone = 0.15 mg of dexamethasone = 0.15 mg of betamethasone [14].
Table 1. Baseline characteristics of the 604 patients with autoimmune diseases treated with glucocorticoid.

| Co-morbidity                        | n = 604(%) |
|-------------------------------------|------------|
| Females                             | 358(59.3)  |
| Mean age (years)                    | 59.5 ± 16.8|
| BW (kg)                             | 55.9 ± 10.9|
| Karnofsky score                     | 79.4 ± 18.3|
| Primary disease                     |            |
| Rheumatic disease                   | 313(51.8)  |
| SLE                                 | 38(6.3)    |
| MCTD                                | 10(1.7)    |
| Polymyositis                        | 18(3.0)    |
| Dermatomyositis                      | 16(2.6)    |
| Vasculitis                          | 46(7.6)    |
| Behçet’s disease                    | 5(0.8)     |
| Systemic sclerosis                  | 12(2.0)    |
| AOSD                                | 13(2.2)    |
| Sjögren’s syndrome                  | 6(1.0)     |
| Rheumatoid arthritis                | 136(22.5)  |
| Autoimmune bullous diseases         | 7(1.2)     |
| Anaphylactoid purpura               | 6(1.0)     |
| Neurological disease                |            |
| Multiple sclerosis                  | 40(7.7)    |
| Myasthenia gravis                   | 20(3.3)    |
| CDP                                 | 10(2.2)    |
| Gastro-Hepatobiliary disease        | 79(13.1)   |
| Ulcerative colitis                  | 20(3.3)    |
| Autoimmune hepatitis                | 51(8.4)    |
| Autoimmune pancreatitis             | 40(7.7)    |
| PBC                                 | 40(7.7)    |
| Interstitial lung disease           | 133(22.0)  |
| Primary Glomerular disease          | 54(8.9)    |
| Rapidly progressive glomerulonephritis | 7(1.2)  |
| Chronic glomerulonephritis          | 18(3.0)    |
| Neprotic syndrome                   | 29(4.8)    |
| Previous TB                         | 34(5.6)    |
| Co-morbidity                        |            |
| Cardiovascular disease              |            |
| CVA                                 | 20(3.3)    |
| Ischemic heart disease              | 25(4.1)    |
| Hypertension                        | 128(21.2)  |
| Arrythmia                           | 19(3.1)    |
| Others                              | 12(2.0)    |
| Metabolic disease                   |            |
| Hyperlipidemia                      | 149(24.7)  |
| Hyperuricemia                       | 44(7.3)    |
| Diabetes                            | 65(10.8)   |
| CKD                                 | 32(5.3)    |

Table 1. Cont.

| Co-morbidity                        | n = 604(%) |
|-------------------------------------|------------|
| Antimicrobial prophyraxis            |            |
| Isoniazid                           | 69(11.4)   |
| Trimethoprim-sulfamethoxazole        | 138(22.8)  |

Statistical analysis

We identified the risk factors of intracellular infections by univariate and multivariate Cox-proportional hazard models analysis. The variables included in the analysis were: age, sex, types of primary autoimmune diseases, comorbidities (diabetes, renal diseases, cardiovascular diseases and interstitial lung diseases), medications (average dose of GC, the use of immunosuppressive agents) and performance status (Karnofsky score). Baseline characteristics were summarized in Table 1. Two-hundred and eighty-three patients from 51 hospitals were enrolled in the J-NHOSAC registry between April 2006 and March 2008. The analysis was performed on all patients with a mean follow-up period of 1.9 ± 0.64 years, for a total of 1105.8 patient-years. There were 358 (59.3%) females and 246 (40.7%) males, with a mean age of 59.5 ± 16.8 years (range 21 to 82 years). All patients received GCs at entry and the mean GCs dose for the first month was 50.4 ± 36.3 mg/day. Concomitant immunosuppressive therapies were summarized in Table 1. Two-hundred and eighty-three patients (46.9%) were treated with immunosuppressants or biologics. The mean dose (lengths) of the immunosuppressive agents as follow: tacrolimus (n = 24); 1.7 ± 0.71 mg/day (376.7 ± 277.7 days), cyclosporine (n = 76); 123.4 ± 39.6 mg/day (409.3 ± 285.6 days), methotrexate (n = 87), 5.7 ± 2.5 mg/week (254.4 ± 368.6 days), oral cyclophosphamide (n = 22); 55.4 mg ± 10.9 mg/day (241.4 ± 288.7 days), intravenous cyclophosphamide (n = 17); 577.1 ± 201.6 mg/week (26.6 ± 1.9 times), etanercept (n = 12) 124.7 mg ± 72.0 mg/month (328.8 ± 261.6 days), infliximab (n = 7) 248.2 mg ± 134.5 mg/month (226.3 ± 167.3 days),...
Table 2. Details of 31 patients with intracellular infections.

| Patient No. | Infection | Site of infection | Patient age/sex | Primary disease | Co-morbidity | Immunosuppressive agents | Months from the start of Steroid | Multi-intracellular infection | Fatal outcome |
|-------------|-----------|------------------|-----------------|-----------------|--------------|--------------------------|--------------------------------|-----------------------------|--------------|
| 1           | CMV       | Viremia           | 73/M            | SLE             |              |                          | 1                             |                             |              |
| 2           | CMV       | Viremia           | 62/M            | Interstitial pulmonia |              |                          | 1                             |                             |              |
| 3           | CMV       | Viremia           | 58/M            | Autoimmune hepatitis |              | Azathioprine             | 1                             |                             |              |
| 4           | CMV       | Viremia           | 82/F            | Systemic sclerosis |              |                          | 2                             |                             |              |
| 5           | CMV       | Viremia           | 79/F            | Vasculitis      |              | Tacrolimus               | 1                             | +                           |              |
| 6           | CMV       | Viremia           | 42/F            | Polymyositis    |              | Cyclosporin              | 1                             | +                           |              |
| 7           | CMV       | Viremia           | 40/F            | Dmamatomyositis |              | Cyclosporin              | 1                             |                             |              |
| 8           | CMV       | Lung              | 76/M            | Vasculitis      |              | Diabetes                 | 3                             | +                           |              |
| 9           | CMV       | Lung              | 71/M            | Intestinal pulmonia |              | Cyclophosphamide         | 2                             | +                           |              |
| 10          | CMV       | Lung              | 70/F            | Rheumatoid arthritis |              | Cyclosporin              | 12                            | +                           | +            |
| 11          | CMV       | Liver             | 81/M            | Vasculitis      |              | Diabetes                 | 2                             | +                           |              |
| 12          | CMV       | Liver             | 51/F            | SLE             |              | Hyperlipidemia           | 1                             |                             |              |
| 13          | CMV       | Colon             | 21/M            | Ulcerative colitis |              |                          | 5                             |                             |              |
| 14          | CMV       | Colon             | 85/F            | Ulcerative colitis |              | CVA                      | 2                             |                             |              |
| 15          | PCP       | Lung              | 72/M            | Intestinal pulmonia |              | Cyclophosphamide         | 3                             |                             |              |
| 16          | PCP       | Lung              | 71/M            | Rheumatoid arthritis |              | Methotrexate, Etanercept | 8                             |                             |              |
| 17          | PCP       | Lung              | 66/M            | Rheumatoid arthritis |              | Methotrexate              | 2                             |                             |              |
| 18          | PCP       | Lung              | 62/M            | Intestinal pulmonia |              | Diabetes, Cyclophosphamide | 3                             | +                           |              |
| 19          | PCP       | Lung              | 61/M            | Intestinal pulmonia |              | Cyclosporin              | 2                             |                             |              |
| 20          | PCP       | Lung              | 81/F            | Vasculitis      |              | Hyperuricemia            | 2                             |                             |              |
| 21          | PCP       | Lung              | 68/F            | Intestinal pulmonia |              | Hyperuricemia            | 19                            |                             | +             |
| 22          | Herpes zoster | Skin            | 74/M            | Rheumatoid arthritis |              | Diabetes, Tacrolimus     | 2                             | +                           | +             |
| 23          | Herpes zoster | Skin            | 58/M            | Intestinal pulmonia |              | Cyclophosphamide         | 12                            |                             |              |
| Patient No. | Infection | Site of infection | Patient age/sex | Primary disease | Cardiovascular disease | Metabolic disease | Immunosuppressant | Biologics | Months from the start of Steroid | Comorbidities | Multi-Intracellular infection | Fatal outcome |
|------------|-----------|------------------|-----------------|----------------|------------------------|------------------|-------------------|-----------|-------------------------------|----------------|--------------------------------|--------------|
| 24         | Herpes zoster | Skin            | 39/M            | Myasthenia gravis |                        |                  |                   |           | 26                            |                |                                |              |
| 25         | Herpes zoster | Skin            | 24/M            | MCTD            |                        |                  | Hyperuricemia     |           | 7                             |                |                                |              |
| 26         | Herpes zoster | Skin            | 77/F            | Autoimmune hepatitis | Hyperuricemia      |                  |                   |           | 14                            |                |                                |              |
| 27         | Herpes zoster | Skin            | 72/F            | Interstitial pulmonia | Hypertension       |                  | Hyperlipidemia    |           | 12                            |                |                                |              |
| 28         | Herpes zoster | Skin            | 53/F            | Interstitial pulmonia | An rhythmia        |                  |                   |           | 1                             |                |                                |              |
| 29         | TB          | Lung             | 91/M            | Autoimmune bullous diseases | CVA                |                  |                   |           | 3                             |                |                                |              |
| 30         | TB          | Lung             | 68/F            | Interstitial pulmonia |                    |                  | Hyperlipidemia    |           | 9                             |                |                                |              |
| 31         | NTM         | Lung             | 70/M            | Rheumatoid arthritis |                    |                  |                   |           | 20                            |                |                                |              |
| 32         | EBV         | Liver            | 58/F            | Vasculitis       | Hypertension        |                  | Hyperlipidemia    |           | 1                             |                |                                |              |
| 33         | Listeria    | Brain            | 73/M            | Vasculitis       | Hypertension        |                  | Hyperuricemia     |           | 6                             |                |                                |              |

Abbreviations: CMV: Cytomegalovirus, PCP: Pneumocystis jiroveci pneumonia, TB: Tuberculosis, NTM: Nontuberculous mycobacterious, EBV: Epstein-Barr virus, SLE: Systemic lupus erythematosus, MCTD: Mixed connective-tissue disease, CVA: Cerebrovascular accident.
adalimumab (n = 3) 87.7 mg ± 2.2 mg/month (288.1 ± 53.6 days). Thirty four patients had experienced previous tuberculosis infection. Prophylaxis was performed in 69 patients using isoniazid (INH) and in 138 patients using TMP/SMX.

**Incidence of intracellular infections**

During the overall follow up periods, 127 serious infections that required hospitalization and/or intravenous antibiotics and/or resulted in death, occurred in 71 patients. The incidence rate of serious infections was 114.8 events/1,000 person-years. These serious infections (n = 127) included 43 intracellular infections. Pathogens identified in 33 patients with intracellular infections are listed in Table 2 and included CMV (n = 14), herpes zoster (n = 7), Epstein–Barr virus (n = 1), *P. jirovecii* infection (n = 7), *Mycobacterium tuberculosis* (n = 2) non-tuberculosis mycobacterium (NTM, n = 1) and *Listeria monocytogenes* (n = 1). The site of these intracellular infections is listed in Table 2. A multi-intracellular infection was reported in eight patients. The intracellular infections occurred earlier and faster than normal infections and 50% of intracellular infections occurred within 4 months of starting GCs. In contrast, non-intracellular serious infections occurred gradually compared with serious intracellular infections (Figure 1).

**Risk factors for intracellular infections**

The case-control study involved 33 patients with serious intracellular infections and 559 patients without serious intracellular infection. To identify differences in risk factors that contributed to the development of intracellular or non-intracellular infections, we compared baseline data between patients with serious intracellular infections and those with non-intracellular serious infections. The positive predictive value (PPV) of mean steroid dose to identify intracellular infections was shown in the receiver operating characteristics (ROC) curve (Figure 2). Cut-off value of steroid dose was made at 30 mg/day based on this ROC curve analysis and this value was entered into the Cox hazard model. Univariate Cox regression analysis showed a significant increased risk of serious intracellular infections with male gender, the presence of diabetes, use of high-dose (≥30 mg/day) of GCs, lower Karnofsky score and lymphocytopenia (<1000/µl). No significant association was found for the use of immunosuppressants or biologics as risk factors. In the multivariate Cox regression analysis, high-dose (≥30 mg/day) of GCs (OR = 2.4 [95% CI, 1.1–5.3]), the presence of diabetes (OR = 2.5 [95% CI, 1.1–5.9]) and lymphocytopenia (<1000/µl, OR = 2.5 [95% CI, 1.2–5.2]) were significantly associated with an increased risk for serious intracellular infections (Table 3).

**Survival curves**

Patients with serious intracellular infections were found to have significant associations to diabetes or low lymphocyte counts compared with those with non-intracellular serious infections. Therefore, Kaplan-Meier survival curves were plotted for the occurrence of the first serious intracellular or non-intracellular infections stratified by the presence of high dose GCs (≥30 mg/day), (Figure 3A), diabetes (Figure 3B) and lymphocytopenia (<1000/µl, Figure 3C). Reduced survival time to the occurrence of first intracellular infections was significant in patients receiving high dose GCs, diabetes or lymphocytopenia. In contrast, reduced survival time to the occurrence of first non-intracellular serious infections was significant only in patients receiving high dose GCs, but not in patients with diabetes or lymphocytopenia.

**Discussion**

GCs are still widely used in the treatment of autoimmune diseases and are thought to be associated with increased risk of infection as well as other well-established adverse effects [15]. However, the extent to which GC contributes to the increased risk of intracellular infections is not completely understood. Despite the fact that intracellular infections rank high amongst common causes of death in immunological diseases [16], they have not been studied specifically in autoimmune diseases. In the current study, we showed that the overall rate of intracellular infections is high in patients with newly diagnosed autoimmune diseases treated with GCs.
Our study showed that intracellular infections occurred more frequently and quickly (most within 4 months from the start of GCs) among patients with autoimmune diseases and some intracellular infections contributed to morbidity and mortality. A high frequency of opportunistic infections complicating autoimmune diseases has been reported previously [17]. The augmented risk is due in part to the underlying immune dysfunction associated with these disorders [18], but also due to immunosuppressive therapies used to treat these disorders. It is often difficult to separate intracellular infections because of underlying diseases (which may be immunosuppressive) and infections related to GC-induced immunosuppression. However, the type of primary autoimmune disease was not identified as a risk factor for intracellular infection. In contrast, we demonstrated that the presence of diabetes, lymphocytopenia and the initial use of high-dose GCs (>30 mg/day), elderly age and male gender were independent predictors for serious intracellular infections in patients with newly diagnosed autoimmune diseases.

To date, there have been few studies evaluating the exposure of GCs in newly diagnosed autoimmune diseases and reporting the rate of intracellular infection. A number of published papers have evaluated the risk of infections in connective tissue diseases [5,19,20], where the exposure of GC, outcomes and risk measurements were not consistent across the studies. Methodological differences between previous studies and ours are that previous investigators used retrospective analysis or hospitalization record techniques to ascertain infection occurrence. In our study, we reviewed each patient’s complete medical records and obtained objective confirmatory evidence of infection including microbiologic cultures and radiographic imaging prospectively. Use of these detailed medical records enabled us to obtain information regarding a broad range of pathogens and infection sites.

The striking incidence of intracellular infections seen in our study suggests the presence of cell-mediated immune deficiency in patients with autoimmune diseases receiving moderate-doses of GCs [21]. From epidemiologic studies, treatment with a daily dose of less than 5 mg of prednisolone or equivalent slightly increased risk of infection [22], whereas daily doses between 20 to 40 mg caused a marked increased risk [23]. However, the true incidence of intracellular infections or their risk factors have not been adequately demonstrated in a prospective study. One of the objectives of this study was to identify possible baseline risk factors for the development of serious intracellular infections in autoimmune disease patients treated with moderate-doses of GCs (>30 mg/day,

### Table 3. Predictors of serious intracellular infection in the COX-hazard model.

| Predictors | Intracellular infection | No intracellular infection | Univariate analysis | Multivariate Analysis |
|------------|-------------------------|---------------------------|---------------------|----------------------|
|            | n = 33                  | n = 559                   | OR (95% CI)         | OR (95% CI)          | p value | p value |
| Age        |                         |                           |                     |                      |         |
|            | 64.5±16.5               | 59.4±16.7                 | 1.255 (0.994–1.585) | 1.843 (0.873–3.891) | 0.056   | 0.109   |
| Gender     |                         |                           |                     |                      |         |
| Male       | 19(57.6%)               | 219(39.2%)                | 2.164 (1.084–4.318) | 2.548 (1.106–5.872) | 0.029   | 0.028   |
| Female     | 14(42.4%)               | 340(60.8%)                |                      |                      |         |
| Primary disease |                  |                           |                     |                      |         |
| Rheumatic disease |       |                           |                     |                      |         |
| Neurological disease |         |                           |                     |                      |         |
| Gastro-Hepatobiliary disease |       |                           |                     |                      |         |
| Interstitial pulmonia |           |                           |                     |                      |         |
| Primary Glomerular disease |         |                           |                     |                      |         |
| Diabetes   | 8(24.2%)                | 57(10.2%)                 | 2.923 (1.316–6.489) | 2.548 (1.106–5.872) | 0.008   | 0.028   |
| Previous TB| 1(3.0%)                 | 33(5.9%)                  | 0.512 (0.070–3.744) |                      | 0.509   |         |
| Treatment  |                         |                           |                     |                      |         |
| Dose of prednisolone (mg/day) |       |                           |                     |                      |         |
| 30 mg/day  | 24(72.7%)               | 269(48.1%)                | 3.043 (1.141–8.550) | 2.417 (1.100–5.308) | 0.004   | 0.028   |
| Immunosuppressant |             |                           |                     |                      |         |
| Biologics  | 14(42.4%)               | 207(37.0%)                | 1.300 (0.652–2.594) |                      | 0.456   |         |
| Karnofsky score |           |                           |                     |                      |         |
| 73.9±18.5  | 79.8±18.3               |                           | 0.836 (0.718–0.975) | 0.901 (0.757–1.072) | 0.022   | 0.239   |
| Laboratory data |                  |                           |                     |                      |         |
| Serum creatinine (mg/dl) |       |                           |                     |                      |         |
| 0.76±0.33  | 0.78±0.64               |                           | 0.999 (0.535–1.865) |                      | 0.998   |         |
| Serum albumin (mg/dl) |       |                           |                     |                      |         |
| 3.30±0.71  | 3.45±0.76               |                           | 0.737 (0.471–1.155) |                      | 0.183   |         |
| Serum IgG (mg/dl) |       |                           |                     |                      |         |
| 1811.5±733.8| 1855.8±866.1 |                           | 1.000 (0.999–1.000) |                      | 0.894   |         |
| WBC (/μl)  | 7637.2±3551.5           | 7769.3±3917.9             | 1.000 (1.000–1.000) |                      | 0.909   |         |
| Lymphocyte count (/μl) |       |                           |                     |                      |         |
| ≤1000      | 12(38.7%)               | 108(20.8%)                | 2.347 (1.139–4.835) | 2.517 (1.207–5.248) | 0.021   | 0.014   |

Abbreviations: OR; Odds ratio, 95% CI; 95% confidence interval Data are expressed as number (percentage) or mean ± SD. The hazard ratios for serious intracellular infection were estimated using the Cox proportional hazard model: Patients (n = 12) without final outcome data were excluded in this analysis. 

doi:10.1371/journal.pone.0078699.t003
mean of first month). Previous studies identified high-doses of GCs, lymphocytopaenia, use of immunosuppressants, low IgG levels and diabetes as independent variables associated with increased risk of intracellular infection [6,16,24–27]. Although the differences between these studies and our results are significant (design, disease evaluated, doses of GCs and variables analysed), it is noteworthy that both studies identified lymphocytopaenia, high doses of GCs and diabetes as independent variables associated with increased risk of intracellular infections [6,26–28]. However, we found no association between concomitant use of immunosuppressive agents or biologics and an increased risk of intracellular infections. How GCs alter the host immune system and influence the development of infection is incompletely understood. Human host immunity against intracellular pathogens is dependent on effective cell-mediated immune responses [29]. GCs can impair phagocyte functions and suppress cell-mediated immunity, possibly increasing the risk of intracellular infections [1].

In general, diabetes is associated with an increased susceptibility to infection [30]. However, no adequate data exists for the effects of diabetes on risk of intracellular infection. Our study clearly demonstrated that the presence of diabetes is a risk factor for intracellular infection in patients treated with GCs. This may be due to abnormalities of the host immune response, particularity defects of neutrophils, macrophages, chemotaxis, adhesion and intracellular killing that are attributed to hyperglycaemia and may explain reduced phagocytosis [31]. Disorders of cell-mediated immunity are often associated with CMV and PCP. CMV is the most common opportunistic pathogen detected in organ transplant recipients and can cause a variety of clinical symptoms in patients with disorders cell-mediated immunity including pneumonitis colitis, hepatitis and retinitis [9]. An increased risk of PCP in association with lymphocytopaenia has been similarly reported in patients with connective tissue diseases [32,33]. Clinicians should maintain a high degree of suspicion for the development of unusual intracellular infections in patients receiving moderate doses of GCs. Initiation of GC therapy requires careful pre-treatment evaluation. Screening for latent tuberculosis, diabetes, cellular-immune dysfunction (lymphocytopaenia) and consideration of prophylaxis should be considered [21,34]. Evaluation and management of suspected intracellular infections in patients receiving newly administered GC treatment must include aggressive diagnostic approaches and empiric treatment.

In conclusion, substantial numbers of intracellular infections occurred in patients with newly diagnosed autoimmune diseases, who were treated with GCs. We showed that patient baseline

Figure 3. Infection (intracellular or non-intracellular) -free survival curves. Figure 3A: Cumulative probability of intracellular or non-intracellular infection-free survival for the complete follow-up period between patients receiving high-dose of GC (≥30 mg/day) and those not receiving high-dose of GC. 3B: Cumulative probability of intracellular or non-intracellular infection-free survival for the complete follow-up period in patients with or without diabetes at time of presentation. 3C: Cumulative probability of intracellular or non-intracellular infection-free survival for the complete follow-up period in patients with or without lymphocytopenia (<1000/μl) at time of presentation.
doi:10.1371/journal.pone.0078699.g003
demographics, such as concomitant diabetes, lymphocytopenia, and initial high-dose GCs (≥30 mg/day) might predict an increased incidence of intracellular infections. Our findings suggest strategies for efficient pre-treatment risk screening, intensive surveillance, prophylaxis and pre-emptive therapy for intracellular infections in patients with newly diagnosed autoimmune diseases, which may eventually lead to the improvement of prognosis and survival.

Acknowledgments

This study could not have been accomplished without the effective and dedicated participation of each of the following contributors: Yukio Ohara, MD (NHO Hokkaido Medical Center); Yoshikazu Araya, MD (NHO Hakodate National Hospital); Noriyuki Chiba, MD (NHO Morioka Hospital); Keiji Chida, MD (NHO Ise city hospital); Muneshige Tobita, MD (NHO Yonezawa Hospital); Takefumi Saito, MD (NHO Barakakishii National Hospital); Manabu Hayashi, MD (NHO Numata Hospital); Misao Kawaguchi, MD (Nishisaitama-chuo National Hospital); Noriko Shi National Hospital); Hidenori Matsuo, MD (NHO Hakodate National Hospital); Nobukiku Nagata, MD (NHO Omuta Hospital); Yutaka Sato, MD (NHO Okita Medical Center); Koich Honda MD (NHO Oita Medical Center); Bon Shoji MD, (NHO Ikawaki Medical Center); Shiuchi Hamada, MD (NHO Kagoshima Medical Center), Isoko Owan, MD (NHO Okinawa National Hospital).

Author Contributions

Conceived and designed the experiments: KM TA SB. Analyzed the data: NI YJ YI Y. Sasaki. Contributed reagents/materials/analysis tools: TK ES T. Miyamura HT YK RM SM SO SY KK Y. Suenaga HT NS HS HY SK FO MK T. Matsui HF ST. Wrote the paper: KM SB.

References

1. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Ballow JR. (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1188–200.
2. Kimberly RP (1991) Mechanisms of action, dosage schedules, and side effects of steroid therapy. Curr Opin Rheumatol 3: 373–9.
3. Klein NC, Go CH, Cunha BA et al. (2001) Infections associated with steroid use. Infect Dis Clin North Am 15: 423–32, viii.
4. Hellmann DB, Petri M, Whiting-O’Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66: 341–8.
5. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2360–76.
6. Doran MF, Croswoson CS, Pond GR, O’Fallon WM, Gabriel SK. (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46: 2294–300.
7. Segal BH, Smeller MC (1997) Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 23: 219–37.
8. Kadoya A, Okada J, Ikuni Y, Kondo H (1996) Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 23: 1186–8.
9. Ramos-Casals M, Cuadrado MJ, Alba P, Pascual S, Selroos O, Baetsi G, Situ J, et al. (2008) Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 87: 511–8.
10. Migita K, Sasaki Y, Ishizuka N, Araki T, Kiyokawa T, et al. Glucocorticoid therapy and the risk of infection in patients with newly-diagnosed autoimmune disease. Medicine (in press).
11. Basch E, Jia X, Holler G, Barz A, Sit L, et al. (2009). Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101: 1624–32.
12. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094–7.
13. Harigui M, Koike R, Miyakata N (2007). Pneumocystis pneumonia associated with influenza in Japan. N Engl J Med 357: 1847–60.
14. Buttgerie F, da Silva JA, Boms M, Burmester GR, Cutole M, et al. (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61: 718–22.
15. McDonough AK, Curtis JR, Saag KG (2008) The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20: 131–7.
16. Falagas ME, Manta KG, Besui GI, Pappas G. (2007) Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26: 663–70.
17. Barber C, Gold WL, Fortin PR (2011) Infections in the lupus patient: prospective on prevention. Curr Opin Rheumatol 23: 358–65.
18. Bielypolus AG, Tsokos GC (1996) Immunophagophagosis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25: 118–36.
19. Goddard B, Coutant-Perronne V, Le Thi Huong D, Guillemin L, Magadar G, et al. (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21: 246–51.
20. Mori T, Kameda H, Ogawa H, Izuka A, Sekiguchi N, et al. (2004) Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. J Rheumatol 31: 1549–51.
21. Carbone J, Laino N, Gallego A, Sarmiento E (2008) Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases. Curr Drug Saf 3: 91–9.
22. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmester GF, et al. (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96: 115–23.
23. Stuck AE, Minder CE, Frey VF (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11: 943–963.
24. Feulner BS (2002) Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 16: 281–91.
25. Komano Y, Harigui M, Koike R, Sugiyama H, Ogawa J, et al. (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61: 305–12.
26. Pryor BD, Bologna SG, Kahle LF (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 39: 1475–82.
27. Takizawa Y, Inokuma S, Tanaka Y, Saito K, Tsuboi A, et al. (2004) Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population. Rheumatology (Oxford) 43: 1373–8.
28. Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, et al. (2012) Pneumocystis jiroveci pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22: 849–58.
29. Pop SM, Kolli JK, Steele C (2006) Pneumocystis: immune recognition and evasion. Int J Biochem Cell Biol 38: 17–22.
30. Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ (2012) The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis 31: 379–88.
31. Geertgens SE, Hoepelman AI (1999) Immune dysfunction in patients with diabetes mellitus. DM. FEMS Immunol Med Microbiol 26: 259–65.
32. Sepkowitz K (1993) Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17: S16–22.
33. Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42: 708–9.
34. Singer NG, McCune WJ (1999) Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Curr Opin Rheumatol 11: 175–8.